Global Inhalation Anaesthesia Market Size USD 1.84 Billion By 2031 | CAGR of 4.9%

Introduction

Inhalation anesthesia is a common method in medical procedures to achieve general anesthesia. It involves administering anesthetic agents through inhalation to induce a state of controlled unconsciousness, ensuring patient comfort and pain relief during surgeries and invasive interventions. The patient inhales these anesthetic agents from gases or volatile liquids designed for anesthesia. The administration of inhalation anesthesia is facilitated by specialized equipment such as anesthesia machines, vaporizers, and breathing circuits. These tools ensure precise delivery and monitoring of the anesthetic agents throughout the procedure. During surgical procedures, anesthetic agents are crucial in controlling various physiological parameters, including pain, breathing, blood pressure, blood flow, and heart rate.

Market Dynamics

Increasing Number of Surgeries Drive the Global Market

The global market for inhalation anesthesia is experiencing a rise due to the increasing number of surgeries being performed worldwide. Surgical procedures often require anesthesia to ensure patient comfort and manage pain during the operation. Factors such as advancements in medical technology, improved healthcare access, and a growing elderly population contribute to the rising demand for surgeries. In addition, the need for anesthesia goes hand in hand with the increasing number of surgeries. Inhalation anesthesia is a commonly used method that allows for the precise administration of anesthetic agents and ensures a smooth transition into and out of anesthesia. It offers effectiveness and controllability, making it a preferred choice in surgical settings.

High Growth Potential Offered by Emerging Economies Creates Tremendous Opportunities

Due to advancements in healthcare infrastructure and a rise in demand for better healthcare, emerging nations in Asia-Pacific and LAMEA present significant development prospects for developing the market for inhalation anesthesia. Increasing surgical procedures, road accidents, and illnesses, including cancer and gastrointestinal problems, also increases the demand for inhalation anesthesia. In addition, rising healthcare and R&D expenditures in developing nations like Brazil, China, and India contribute to the expansion of the inhalation anesthesia market. These investments paved the way for the creation of cutting-edge anesthetic technology, enhanced anesthesia delivery systems, and the launch of ground-breaking products.

Regional Analysis

North America is the most significant global inhalation anesthesia market shareholder and is estimated to grow at a CAGR of 5.89% over the forecast period. The North American inhalation anesthesia market is experiencing significant growth, driven by several key factors. One of the main motivators is the increase in government funds allocated for research and development (R&D) of novel inhalation anesthesia. These funds support the development of advanced anesthesia products and technologies, facilitating innovation in the market and driving its growth. In addition, the region has witnessed a rise in cancer incidence. Cancer treatments often require surgical procedures, and anesthesia is crucial in ensuring patient comfort and safety during these interventions. As the prevalence of cancer continues to rise, the demand for surgical procedures and disease treatments also rises, consequently boosting the demand for inhalation anesthesia.

Furthermore, North America is highly accepting of technological advancements in the healthcare sector. The region boasts a well-established healthcare infrastructure and a strong emphasis on adopting innovative medical technologies. This favorable environment creates opportunities for manufacturers to introduce advanced inhalation anesthesia products that cater to the evolving needs of healthcare providers and patients.

Europe is estimated to exhibit a CAGR of 4.01% over the forecast period. Europe holds a significant share of the inhalation anesthesia market and is expected to grow steadily in the coming years. The region benefits from several factors that contribute to its market growth. The European governments strongly focus on treating various disorders, leading to increased investments in healthcare systems and rising healthcare expenditures. These factors create favorable conditions for adopting and using inhalation anesthesia. In addition, Europe is known for its well-established healthcare infrastructure, which supports the implementation of advanced medical procedures, including inhalation anesthesia. The presence of advanced hospitals and skilled healthcare professionals ensures the safe and effective administration of anesthesia during surgeries and other medical interventions.

Key Highlights

• The global inhalation anesthesia market was valued at USD 1.35 billion in 2022. It is estimated to reach USD 1.84 billion by 2031, growing at a CAGR of 4.9% during the forecast period (2023–2031).
• Based on products, the global inhalation anesthesia market is bifurcated into sevoflurane, desflurane, isoflurane, and nitrous oxide. The sevoflurane segment dominates the global market and is estimated to grow at a CAGR of 3.5% over the forecast period.
• Based on applications, the global inhalation anesthesia market is bifurcated into induction and maintenance. The induction segment owns the highest market share and is estimated to grow at a CAGR of 3.8% over the forecast period.
• North America is the most significant global inhalation anesthesia market shareholder and is estimated to grow at a CAGR of 5.89% over the forecast period.

Competitive Players

Competitive Players

The key players in the global inhalation anesthesia market are AbbVie Inc., Baxter International Inc., Fresenius SE & Co. KGaA., Halocarbon Products Corporation, Hikma Pharmaceuticals PLC., Jiangsu Hengrui Medicine Co., Ltd., Lunan Pharmaceutical Group Co. Ltd, Novartis AG, Piramal Enterprises Ltd, and Troikaa Pharmaceuticals Ltd.

Recent Developments

Market News

• In March 2023, Pfizer announced the launch of its new Sevoflurane Invenio delivery system. The system is designed to provide a more consistent and reliable delivery of sevoflurane, a commonly used inhalation anesthetic.
• In February 2023, Baxter announced the launch of its new Isoflurane Avance delivery system. The system is designed to provide a more consistent and reliable delivery of isoflurane, a commonly used inhalation anesthetic.

Segmentation

Global Inhalation Anaesthesia Market: Segmentation

By Product

• Sevoflurane
• Desflurane
• Isoflurane
• Nitrous Oxide

By Applications

• Induction
• Maintenance

By End-Users

• Hospitals
• Ambulatory Surgical Centers

By Regions

• North America
• Europe
• Asia-Pacific
• Latin America
• The Middle East and Africa